Rabies vaccine
As of the edition of 20 October 2026, Rabies vaccine is a vaccine component: marketed, first approved in 1997 (US); US protection ended in 2009.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1997
- Kind
- Vaccine component
- Brand name
- Rabavert
- First approved
- 20 October 1997 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Sanofi; 3 holders in all
- Registered trials
- 37, 0 stopped early
- Disease areas
- Infections; Animal diseases; Digestive system; Immune system; Blood and lymph; Cancer
US protection
US protection ended in 2009.
US protection ended in 2009, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Bavarian Nordic. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 6 | 0 | 0 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 11 | 7 | 3 | 0 |
| Phase 3 | 10 | 7 | 3 | 0 |
| Phase 4 | 4 | 3 | 0 | 0 |
| All trials | 37 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| GSK | Earlier holder | 1997 to now |
| Emergent Biosolutions | Later holder | 1998 to now |
| Sanofi | Later holder and Lead sponsor of trials | 2000 to now |
| Bavarian Nordic | Acquired holder | 2021 to now |